Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Assessing and improving deep domain alignment in ultrasound via simulation diversity.

Ultrasonics·2026
Same author

Training-oriented framework for brachytherapy treatment planning in soft tissue sarcoma.

Brachytherapy·2026
Same author

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

Behavioral and transcriptomic markers of susceptibility to escalate fentanyl intake.

Translational psychiatry·2026
Same author

Novel Voxel-Based MRI Risk Score LADCT<sub>2</sub> as a Tool for Prediction of Prostate Cancer: A Proof of Concept With Retrospective Study.

Cancer control : journal of the Moffitt Cancer Center·2026

Related Experiment Video

Updated: Jun 30, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.8K

Novel Postoperative Hypofractionated Accelerated Radiation Dose-Painting Approach for Soft Tissue Sarcoma.

Matthew Mills1, Justin Miller1, Casey Liveringhouse1

  • 1Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Advances in Radiation Oncology
|March 18, 2024
PubMed
Summary

Hypofractionated accelerated radiation therapy (HARD) is a safe and effective treatment for soft tissue sarcomas (STS). This approach offers dosimetric advantages and reduces treatment time and cost compared to conventional methods.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.7K

Related Experiment Videos

Last Updated: Jun 30, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.8K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

15.7K

Area of Science:

  • Radiation Oncology
  • Medical Physics
  • Surgical Oncology

Background:

  • Hypofractionated radiation therapy (RT) presents advantages for soft tissue sarcoma (STS) treatment, including improved patient convenience and cost-effectiveness.
  • The lower alpha/beta ratio of STS makes it suitable for hypofractionated RT regimens.

Purpose of the Study:

  • To evaluate the acute toxicity and efficacy of a hypofractionated accelerated RT dose-painting (HARD) approach for postoperative STS treatment.
  • To compare dosimetric indices and clinical outcomes of HARD versus conventional sequential boost RT.

Main Methods:

  • Retrospective review of 53 STS patients undergoing resection and postoperative RT.
  • Implementation of HARD dose-painting (50.4-70 Gy in 28 fractions) replacing standard sequential boost (50 Gy + 14-20 Gy).
  • Dosimetric comparison of HARD vs. sequential boost plans in the first 10 patients; time-to-event outcomes analyzed using Kaplan-Meier.

Main Results:

  • Median follow-up was 25.2 months; most patients had high-grade extremity STS with close or R1 margins.
  • Two-year outcomes: 100% local control, 92% regional control, 68% distant control, 86% overall survival.
  • HARD demonstrated significantly lower total V50 Gy, bone V50, and maximum skin dose compared to sequential boost, with a 4-7 fraction reduction in treatment time and average cost savings of $3056.

Conclusions:

  • The HARD regimen is a safe postoperative treatment for STS, exhibiting dosimetric advantages over conventional sequential boost RT.
  • HARD offers benefits in cost, convenience, and potentially improved long-term toxicity for STS patients.
  • This hypofractionated approach may enhance the therapeutic ratio in STS management.